ImmuneSense COVID-19 Variant Study

Completed

Conditions studied: Covid19

In brief

This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.

Key facts

Study ID

NCT05054088

Run by

Adaptive Biotechnologies

People needed

203

Starts

2021-10-12

Expected to finish

2022-07-28

Last updated by the study team

2022-12-07

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants must satisfy the following criteria to be enrolled in the study:
• i. Individuals who have tested positive for SARS-CoV-2 via EUA RT-PCR testing. ii. Male and female participants of any race and ethnicity between 18 to 89 years of age (inclusive) at the time of enrollment in the study. iii. Must be able to communicate with the investigator, understand, and comply with the requirements of the study. iv. Must be able to provide estimated date of symptom onset. v. Must be available for specimen collection greater than 14 days (i.e., 15 days inclusive onward) and less than 107 days (i.e., 106 days inclusive or less) after first exhibiting symptoms of confirmed SARS-CoV-2 infection.

You may not qualify if…

• The presence of any of the following will exclude a participant from enrollment:
• Individuals who did not test positive for SARS-CoV-2 on EUA RT-PCR.
• Protected populations including pregnant women, prisoners, mentally disabled persons, and wards-of-the state.
• Any significant condition, laboratory abnormality, or psychiatric illness that would prevent the participant from safely participating in the study.
• Exposure to a SARS-CoV-2 investigational drug (new chemical entity) within 60 days prior to enrollment at the discretion of the Sponsor.
• Receipt of immunosuppressive medications, such as, but not limited to, recent moderate- or high-dose systemic steroids or immunomodulators within 1 month prior to enrollment at the discretion of the Sponsor.
• Treatment with immunosuppressants/ immunomodulators that do not impact T cells or B cells may be allowed at the discretion of the Sponsor.
• Steroid formulations including low-dose oral steroids (≤ 10 mg prednisone equivalents per day), inhaled steroids, or topical steroids are not considered exclusionary. Doses >10 and <20 mg prednisone equivalents per day, must receive Sponsor approval.

Where it is running

• Decentralized Trial Model- Phoenix — Phoenix, Arizona, United States
• Decentralized Trial Model- Fullerton — Fullerton, California, United States
• Decentralized Trial Model- California — Los Angeles, California, United States
• Decentralized Trial Model- Modesto — Modesto, California, United States
• Decentralized Trial Model- Sacramento — Sacramento, California, United States
• Decentralized Trial Model- California — San Diego, California, United States
• Decentralized Trial Model- San Francisco — San Francisco, California, United States
• Decentralized Trial Model- Denver — Denver, Colorado, United States
• Decentralized Trial Model - Washington D.C. — Washington D.C., District of Columbia, United States
• Decentralized Trial Model- Florida — Miami, Florida, United States
• Decentralized Clinical Trial Model- New York City — New York, New York, United States
• Decentralized Trial Model- Portland — Portland, Oregon, United States
• Decentralized Trial Model- Utah — Salt Lake City, Utah, United States
• Decentralized Trial Model- Seattle — Seattle, Washington, United States
• Decentralized Trial Model- Vancouver, WA — Vancouver, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.